Hemophilia treatment comparison study pulled before it began
NCT ID NCT04690322
First seen Apr 09, 2026 · Last updated Jun 07, 2026 · Updated 12 times
Summary
This study aimed to compare two standard treatments for severe hemophilia A—extended half-life factor VIII and non-factor VIII therapies—to see which better protects joint health and controls bleeding. It was designed for children under 18 without existing joint damage. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75235, United States
Conditions
Explore the condition pages connected to this study.